Earnings call: Longeveron reports Q1 2024 results, optimistic on Lomecel-B
Longeveron Inc. (LGVN), a leader in regenerative medicine, recently discussed its first-quarter financial results for 2024 and provided updates on its business operations. The company's lead development compound, Lomecel-B, has shown promising results …